Baili Tianheng (688506.SH): Application for the marketing of Iza-bren for the treatment of locally advanced or metastatic triple-negative breast cancer has been accepted.

Zhtng Cijng APP news, Baltinhng (688506.SH) announced that recently, the company received the "Acceptance Notice" issued by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. The company's independently developed global first-in-class, new concept, and the only EGFRHER3 dual-target ADC (iza-bren) entering Phase III clinical stage has officially been accepted for market application (NDA).